Finch Therapeutics Group (FNCH) Competitors $11.00 -0.30 (-2.65%) (As of 05:33 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends FNCH vs. EPIX, UNCY, DBVT, ATRA, CUE, VTGN, VOR, THTX, RVPH, and IVVDShould you be buying Finch Therapeutics Group stock or one of its competitors? The main competitors of Finch Therapeutics Group include ESSA Pharma (EPIX), Unicycive Therapeutics (UNCY), DBV Technologies (DBVT), Atara Biotherapeutics (ATRA), Cue Biopharma (CUE), Vistagen Therapeutics (VTGN), Vor Biopharma (VOR), Theratechnologies (THTX), Reviva Pharmaceuticals (RVPH), and Invivyd (IVVD). These companies are all part of the "pharmaceutical products" industry. Finch Therapeutics Group vs. ESSA Pharma Unicycive Therapeutics DBV Technologies Atara Biotherapeutics Cue Biopharma Vistagen Therapeutics Vor Biopharma Theratechnologies Reviva Pharmaceuticals Invivyd ESSA Pharma (NASDAQ:EPIX) and Finch Therapeutics Group (NASDAQ:FNCH) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, earnings, valuation, risk, community ranking, profitability and dividends. Which has better earnings and valuation, EPIX or FNCH? ESSA Pharma has higher earnings, but lower revenue than Finch Therapeutics Group. ESSA Pharma is trading at a lower price-to-earnings ratio than Finch Therapeutics Group, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioESSA PharmaN/AN/A-$26.58M-$0.62-2.60Finch Therapeutics Group$110K160.60-$74.75M-$8.82-1.25 Does the media prefer EPIX or FNCH? In the previous week, ESSA Pharma had 6 more articles in the media than Finch Therapeutics Group. MarketBeat recorded 6 mentions for ESSA Pharma and 0 mentions for Finch Therapeutics Group. ESSA Pharma's average media sentiment score of 0.64 beat Finch Therapeutics Group's score of 0.00 indicating that ESSA Pharma is being referred to more favorably in the media. Company Overall Sentiment ESSA Pharma Positive Finch Therapeutics Group Neutral Do analysts recommend EPIX or FNCH? ESSA Pharma currently has a consensus target price of $9.50, suggesting a potential upside of 490.06%. Given ESSA Pharma's stronger consensus rating and higher possible upside, equities analysts clearly believe ESSA Pharma is more favorable than Finch Therapeutics Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ESSA Pharma 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Finch Therapeutics Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more risk & volatility, EPIX or FNCH? ESSA Pharma has a beta of 1.62, suggesting that its stock price is 62% more volatile than the S&P 500. Comparatively, Finch Therapeutics Group has a beta of 1.29, suggesting that its stock price is 29% more volatile than the S&P 500. Do institutionals & insiders hold more shares of EPIX or FNCH? 75.1% of ESSA Pharma shares are owned by institutional investors. Comparatively, 21.8% of Finch Therapeutics Group shares are owned by institutional investors. 14.7% of ESSA Pharma shares are owned by insiders. Comparatively, 44.9% of Finch Therapeutics Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the MarketBeat Community favor EPIX or FNCH? ESSA Pharma received 339 more outperform votes than Finch Therapeutics Group when rated by MarketBeat users. Likewise, 75.87% of users gave ESSA Pharma an outperform vote while only 52.63% of users gave Finch Therapeutics Group an outperform vote. CompanyUnderperformOutperformESSA PharmaOutperform Votes34975.87% Underperform Votes11124.13% Finch Therapeutics GroupOutperform Votes1052.63% Underperform Votes947.37% Is EPIX or FNCH more profitable? ESSA Pharma's return on equity of -20.17% beat Finch Therapeutics Group's return on equity.Company Net Margins Return on Equity Return on Assets ESSA PharmaN/A -20.17% -19.62% Finch Therapeutics Group N/A -69.14%-26.92% SummaryESSA Pharma beats Finch Therapeutics Group on 12 of the 15 factors compared between the two stocks. Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life-changing for those who are prepared. Why? Because altcoin prices are about to explode.>> Register for the Workshop Now Get Finch Therapeutics Group News Delivered to You Automatically Sign up to receive the latest news and ratings for FNCH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FNCH vs. The Competition Export to ExcelMetricFinch Therapeutics GroupBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$17.67M$2.88B$5.03B$8.96BDividend YieldN/A1.85%4.83%4.06%P/E Ratio-1.2545.91133.4516.94Price / Sales160.60400.741,120.44116.28Price / CashN/A182.1340.6337.95Price / Book0.773.744.754.71Net Income-$74.75M-$42.03M$118.34M$225.20M7 Day Performance-6.28%-7.86%11.87%-3.77%1 Month Performance-1.61%2.80%11.93%4.45%1 Year Performance209.86%16.52%31.39%18.66% Finch Therapeutics Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FNCHFinch Therapeutics GroupN/A$11.00-2.7%N/A+228.5%$17.67M$110,000.00-1.25190EPIXESSA Pharma3.5015 of 5 stars$1.70flat$11.67+586.3%-73.7%$75.43MN/A0.0050Earnings ReportNews CoverageUNCYUnicycive Therapeutics3.7655 of 5 stars$0.73flat$5.13+605.9%+22.2%$75.36M$680,000.00-0.759DBVTDBV Technologies3.6228 of 5 stars$3.61-1.4%$30.00+731.0%-61.2%$74.26M$15.73M0.00106Analyst ForecastATRAAtara Biotherapeutics3.8277 of 5 stars$12.82-1.6%$16.67+30.0%-31.0%$73.84M$8.57M0.00165CUECue Biopharma4.663 of 5 stars$1.14+3.6%$5.00+338.6%-62.5%$72.22M$5.49M0.0060Short Interest ↓News CoveragePositive NewsGap DownVTGNVistagen Therapeutics1.0784 of 5 stars$2.59-0.4%N/A-51.2%$72.11M$1.06M0.0040VORVor Biopharma2.3734 of 5 stars$1.04+26.9%$11.36+992.0%-56.6%$71.42MN/A-0.62140High Trading VolumeTHTXTheratechnologiesN/A$1.55+9.2%N/A+1.9%$71.27M$81.76M0.00140Positive NewsRVPHReviva Pharmaceuticals3.253 of 5 stars$2.12+28.5%$15.50+631.1%-63.0%$70.89MN/A-2.225News CoverageGap UpHigh Trading VolumeIVVDInvivyd3.6983 of 5 stars$0.59+1.7%$7.89+1,236.9%-69.9%$70.58MN/A-0.31100Gap Up Related Companies and Tools Related Companies EPIX Alternatives UNCY Alternatives DBVT Alternatives ATRA Alternatives CUE Alternatives VTGN Alternatives VOR Alternatives THTX Alternatives RVPH Alternatives IVVD Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:FNCH) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | SponsoredDeFi Coin on Verge of Breakout!The blueprint for millionaires is here. Don't let this be the missed opportunity you regret for years. Crypto 101 Media | SponsoredMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is ...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | Sponsored“The Last Retirement Stock You’ll Ever Need”We've just released a critical trade alert about a groundbreaking AI investment opportunity. So, I wanted t...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Finch Therapeutics Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Finch Therapeutics Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free FNCH Stock Alerts